June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Za, T.

PB2161 TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA WITH HIGH DOSES OF CYCLOPHOPHAMIDE, BORTEZOMIB AND DEXAMETHASONE FOLLOWED BY DOUBLE AUTOLOGOUS HSCT

Pagano, L.; Maraglino, A. E. M.; Criscuolo, M.; More

HemaSphere. 3(S1):971, June 2019.

Author:
Zabaleta, A.

S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3(S1):12-13, June 2019.

PS1348 DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM)

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3(S1):615-616, June 2019.

PS1402 OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM

Peña, C.; Schutz, N.P.; Bove, V.; More

HemaSphere. 3(S1):643-644, June 2019.

Author:
Zabalza, A.
Author:
Zabek, A.

PF524 EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3(S1):214-215, June 2019.

Author:
Zaccaria, G.M.

PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.; Zaccaria, G.M.; Barbero, D.; More

HemaSphere. 3(S1):569-570, June 2019.

PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3(S1):599, June 2019.

Author:
Zach, O.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

Author:
Zachee, P.

PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL

Cervantes, F.; Gisslinger, H.; Radinoff, A.; More

HemaSphere. 3(S1):675-676, June 2019.

Author:
Zacheo, I.
Author:
Zackova, D.

PF414 DNA-BASED BCR-ABL1 ANALYSIS PROVIDES A “TRAFFIC LIGHT” STRATIFICATION MODEL FOR CHRONIC MYELOID LEUKEMIA WITH IMPLICATIONS FOR TREATMENT FREE REMISSION

Machova Polakova, K.; Zizkova, H.; Zuna, J.; More

HemaSphere. 3(S1):159, June 2019.

Author:
Žácková, M.
Author:
Zafar, F.

PF631 HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

Reece, D.; Bahlis, N.J.; Samaras, C.; More

HemaSphere. 3(S1):268-269, June 2019.

Author:
Zagaria, A.

PF653 TARGETED NEXT-GENERATION SEQUENCING IDENTIFIES NOVEL GENE VARIANTS IN JAK2V617F NEGATIVE PATIENTS WITH ERYTHROCYTOSIS AND JAK2 GGCC_46/1 HAPLOTYPE

Anelli, L.; Orsini, P.; Minervini, A.; More

HemaSphere. 3(S1):279-280, June 2019.

Author:
Zagloul, N.
Author:
Zagotto, G.

PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)

Pagano, M.A.; Tibaldi, E.; Brunati, A.M.; More

HemaSphere. 3(S1):518-519, June 2019.

Author:
Zagozdzon, R.

PF524 EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3(S1):214-215, June 2019.

Author:
Zaharov, O.

PB2014 INTERFERON-FREE ANTIVIRAL THERAPY IN THE TREATMENT OF RELAPSE HEPATITIS C VIRUS ASSOCIATED MARGINAL ZONE LYMPHOMA

Lepkov, S.; Subortceva, I.; Tumian, G.; More

HemaSphere. 3(S1):911, June 2019.

PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Moreau, P.; Stewart, A.K.; Dimopoulos, M.-A.; More

HemaSphere. 3(S1):260, June 2019.

Author:
Zaidi, A.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Zaitseva, G.
Author:
Zaja, F.

S101 EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: RESULTS OF THE PHASE III MABCUTE STUDY

Rule, S.; Gois Barreto, W.; Briones, J.; More

HemaSphere. 3(S1):1, June 2019.

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3(S1):3, June 2019.

PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3(S1):302, June 2019.

Author:
Zak, P.
Author:
Žák, P.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

Author:
Zaka, A.

S144 A MULTICENTRE, RANDOMIZED, NON-INFERIORITY TRIAL COMPARING THE EFFICACY OF DEFERIPRONE VERSUS DEFERASIROX IN PEDIATRIC PATIENTS AFFECTED BY TRANSFUSION-DEPENDENT HEMOGLOBINOPATHIES (DEEP-2 TRIAL)

Kattamis, A.; Felisi, M.; Reggiardo, G.; More

HemaSphere. 3(S1):23-24, June 2019.

Author:
Zakharko, E.
Author:
Zakharov, S.
Author:
Zaki, I.
Author:
Zaki, M.

PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL

Dimopoulos, M.; Weisel, K.; Moreau, P.; More

HemaSphere. 3(S1):250-251, June 2019.

Author:
Zaliova, M.

PF162 FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA

Zaliova, M.; Potuckova, E.; Lukes, J. Jr.; More

HemaSphere. 3(S1):33, June 2019.

PF176 MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3(S1):40-41, June 2019.

Author:
Zalyalov, Y.
Author:
Zalyalov, Y.R.

PB1825 NIVOLUMAB IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSICAL HODGKIN LYMPHOMA

Yakimovich, K.P.; Mikhailova, N.B.; Lepik, K.V.; More

HemaSphere. 3(S1):835-836, June 2019.

Author:
Zamagni, E.

PF560 A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS

Martello, M.; Termini, R.; Borsi, E.; More

HemaSphere. 3(S1):232, June 2019.

S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Gay, F.; Cerrato, C.; Rota Scalabrini, D.; More

HemaSphere. 3(S1):390-391, June 2019.

PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3(S1):616, June 2019.

Author:
Zambello, R.

PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3(S1):244, June 2019.

PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)

Pagano, M.A.; Tibaldi, E.; Brunati, A.M.; More

HemaSphere. 3(S1):518-519, June 2019.

PS1431 IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS

Barila’, G.; Bonaldi, L.; Martines, A.; More

HemaSphere. 3(S1):659, June 2019.

Author:
Zambrano, W.J.
Author:
Zamò, A.

PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.; Zaccaria, G.M.; Barbero, D.; More

HemaSphere. 3(S1):569-570, June 2019.

Author:
Zamora, L.

PS1171 TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB

Estrada, N.; Xicoy, B.; García, O.; More

HemaSphere. 3(S1):532-533, June 2019.

Author:
Zamora, R.
Author:
Zanabilli, J.
Author:
Zanaglio, C.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT)

Turra, A.; Polverelli, N.; Corvini, F.; More

HemaSphere. 3(S1):711, June 2019.

Author:
Zanardi, S.
Author:
Zang, D.Y.
Author:
Zangari, M.

PS1386 CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA

Van Rhee, F.; Wang, H.; Thanendrarajan, S.; More

HemaSphere. 3(S1):635, June 2019.

Author:
Zanghì, P.

PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3(S1):65-66, June 2019.

Author:
Zanni, M.

S1597 PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL)

Balzarotti, M.; Spina, M.; Monagheddu, C.; More

HemaSphere. 3(S1):735, June 2019.

Author:
Zanotti, R.

PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3(S1):662-663, June 2019.

PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES

Tanasi, I.; Bonifacio, M.; Pizzolato, M.; More

HemaSphere. 3(S1):673, June 2019.

Author:
Zanwar, S.

PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Castillo, J.; Abeykoon, J.; Gustine, J.; More

HemaSphere. 3(S1):194-195, June 2019.

Author:
Zapata, N.

PB1739 SURVIVAL ANALYSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH INTENSIVE CHEMOTHERAPY: RESULTS OF A MEXICAN NATIONAL AML REGISTRY.

Demichelis, R.; Zapata, N.; Leyto, F.; More

HemaSphere. 3(S1):800, June 2019.

PB1773 OVERAL SURVIVAL OF MEXICAN NATIONAL REGISTRY OF ACUTE PROMYEOLOCYTIC LEUKEMIA, AN ANALYSIS OF 324 CASES

Zapata, N.; Montaño, E.; Ramos, C.; More

HemaSphere. 3(S1):814, June 2019.

Author:
Zapico, E.

PB1966 HYPERVITAMINOSIS B12 MEDIATED BY INMUNE COMPLEXES IN PATIENTS WITH VITAMIN B12 DEFIENCY, VALUE OF HOMOCYSTEIN AND METHYLMALONIC ACID ASSESSMENT

Legarda, Campo M.A.; Payán-Pernía, S.; Sánchez García, J.; More

HemaSphere. 3(S1):893-894, June 2019.

Author:
Zappasodi, P.

S1637 A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP

Marchesi, F.; Cattaneo, C.; Criscuolo, M.; More

HemaSphere. 3(S1):756-757, June 2019.